Langaware
Langaware is an AI healthcare technology company that detects and monitors neurodegenerative diseases and mental health conditions by analyzing speech and voice biomarkers, serving healthcare providers, payors, life sciences firms, digital health platforms, and corporate wellness clients across the US and Greece.
- Company typePrivate
- Founded2017
- HeadquartersMenlo Park, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Langaware does
Langaware is an AI-driven healthcare technology company that detects and monitors neurodegenerative and mental health conditions through proprietary speech and voice biomarker analysis. Founded in 2017 and operating from the United States with a wholly-owned Greek branch, the company developed the LANGaware Platform, which ingests brief audio recordings (patients describing an image or daily activity), converts them to text via ASR, and processes them through a multimodal machine learning pipeline (Random Forest, Neural Networks, Gradient Boosting) that maps proprietary multilingual digital biomarkers to cognitive and mental health categories. The platform currently targets Mild Cognitive Impairment (MCI), Alzheimer's disease, and Depression, delivering a 7-data-point report within approximately three minutes and reporting 90% sensitivity and 85% specificity for Dementia detection and 83% sensitivity and 80% specificity for Depression detection.
The product surface is organized into two core solutions — the Cognitive Health Solution for MCI/AD screening and the Mental Health Solution for depression and anxiety — both running on the same underlying platform. Langaware serves five target segments: healthcare providers (hospitals, primary care, nursing homes, home healthcare, telemedicine), payors, life sciences firms (for clinical trial participant screening), digital health platforms (for white-label/embedded integration), and corporate wellness programs. Go-to-market is sales-led, anchored by direct enterprise demos with a complementary self-serve "Take The Test" option, and pricing is custom-quoted on an annual subscription basis (no publicly disclosed tiers).
The company is venture-backed, having raised approximately $4.34 million across four rounds between 2019 and 2023, with the most recent being a $2 million seed round in October 2023 led by Eleven Ventures with participation from Metavallon VC. It holds granted US Patent US11114113 and EU Patent EP3809411B1 on its multilingual detection system, maintains ISO 27001 (information security) and ISO 22301 (business continuity) certifications, and has published peer-reviewed clinical validation in Alzheimer's & Dementia, SAGE journals, and PLOS ONE. The company is founder-led by CEO Vassiliki Rentoumi PhD, a computational linguistics and NLP researcher affiliated with the SKEL AI Lab at NCSR Demokritos.
Langaware firmographics
Firmographics- Name
- Langaware
- Legal name
- LANGaware Health, Inc.
- Website
- https://langaware.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Langaware is an AI healthcare technology company that detects and monitors neurodegenerative diseases and mental health conditions by analyzing speech and voice biomarkers, serving healthcare providers, payors, life sciences firms, digital health platforms, and corporate wellness clients across the US and Greece.
- Ownership category
- akta.pro rank
Langaware industry classification
Industry- Product category
- Digital Health - Cognitive & Mental Health Screening Software
- NAICS
- Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (5182)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Speech Recognition, Dictation & Medical Transcription Platforms (HLACAAAI)
- akta.pro secondary industry
- eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB)
Keywords
Where Langaware is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Langaware business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- AI Health Screening Platform SaaS: LANGaware provides an AI-driven screening platform to healthcare providers, payors, life sciences companies, and corporate wellness clients on a subscription or per-assessment basis, though specific commercial terms are not publicly disclosed.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise subscription — pricing not publicly disclosed, custom quotes provided upon demo request. |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
Langaware product offering
Product offeringCore offering
LANGaware provides an AI-driven speech and language analysis platform that detects and monitors digital biomarkers of cognitive and mental health conditions. Customers record a brief speaking task; the platform applies proprietary multilingual biomarkers and machine learning classifiers to produce a clinical decision-support report (7 data points) for early detection of Mild Cognitive Impairment, Alzheimer's disease, and Depression. The platform is offered as enterprise SaaS to healthcare providers, payors, life sciences companies, corporate wellness programs, and digital health platforms, with an additional self-serve test option.
Product overview
LANGaware offers a unified AI-driven platform for cognitive and mental health screening through speech and voice biomarker analysis. The platform consists of two core solutions: the Cognitive Health Solution for early detection of Mild Cognitive Impairment and Alzheimer's disease, and the Mental Health Solution for depression and anxiety screening. Both solutions operate on the same LANGaware Platform technology, which processes audio samples and applies multimodal ML pipelines to generate comprehensive reports with 7 data points for healthcare decision support.
Differentiator
Problem solved
Functional benefit
Products and services
- LANGaware Platform AI-driven platform that analyzes speech and voice biomarkers from short audio recordings to provide early detection and monitoring of cognitive and mental health conditions, including Alzheimer's disease, Mild Cognitive Impairment, and Depression. The platform generates a comprehensive report with 7 data points within approximately 3 minutes and is used by healthcare providers, payors, life sciences firms, digital health platforms, and corporate wellness programs.
- Mental Health Solution AI-powered depression and anxiety screening solution that leverages voice and speech biomarkers to support early awareness and detection of mental health conditions through scalable, accessible testing. Built on the LANGaware Platform and intended for healthcare providers, payors, corporate wellness programs, and digital health platforms.
- Cognitive Health Solution Memory loss assessment platform that analyzes speech samples to objectively identify cognitive change indicators associated with Mild Cognitive Impairment and Alzheimer's disease. Built on the LANGaware Platform, it provides decision-support reports with multiple data points for healthcare providers.
Quantifiable outcome
- Dementia detection achieves 90% Sensitivity and 85% Specificity
- +3 more outcomes
Companies that use Langaware
Customer profileNamed customers2 records
Segments5 records
Ideal customer profiles5 records
Langaware technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
Langaware partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights6 records
Langaware competitors and assessment
Company assessmentDirect peers
- Cambridge Cognition: UK-based provider of digital cognitive assessments and voice biomarker tools (acquired Winterlight Labs). Directly comparable to Langaware on speech-based cognitive screening for clinical trials and healthcare, with broader language coverage and FDA-cleared products.
- Altoida: Digital cognitive assessment platform using AI/ML on smartphone-based tasks to detect MCI and Alzheimer's risk. Directly comparable on AI-driven early cognitive screening with FDA Breakthrough Device designation, competing for similar provider and pharma channels.
- Cogstate: Commercial cognitive testing technology used in clinical trials, healthcare, and research, with FDA-cleared products. Direct competitor for Langaware's life sciences and provider screening use cases with deeper trial-deployment track record.
- Linus Health: Digital brain health platform combining digital cognitive assessments (e.g., DCTclock) with AI-based speech/language analysis for early detection of cognitive impairment. Closest direct competitor given speech-based dementia screening overlap and US provider/payor focus.
- BrainCheck: Digital cognitive assessment platform for clinicians to detect and manage cognitive impairment, including MCI and dementia. Comparable on provider-focused cognitive screening workflow, with broader US clinic footprint.
- Ellipsis Health: Voice-based mental health biomarker company using speech analysis to detect anxiety and depression. Direct overlap on the depression/anxiety screening side of Langaware's platform, with similar enterprise and payor sales motion.
- Kintsugi: Voice biomarker platform for detecting depression and anxiety from short voice samples, sold into payors, providers, and telehealth. Comparable on voice-based mental health screening technology and B2B healthcare go-to-market.
- Neurotrack: Digital cognitive health company offering memory and cognitive assessments, including a 5-minute cognitive screening test. Overlaps on AI-driven cognitive screening for providers and consumers, with an established US presence.
Broad incumbents
- Suki AI: AI voice assistant for clinicians using speech recognition and NLP to generate clinical notes. Comparable on healthcare-focused speech/NLP technology, but operates upstream as clinician documentation tooling rather than patient cognitive screening.
Emerging players
- NeuraLight: AI-driven oculometric platform for neurological disease detection and monitoring, including Alzheimer's and Parkinson's. Comparable as an emerging digital biomarker neurology platform pursuing similar pharma clinical-trial and provider channels.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Langaware social profiles
Digital presenceLangaware compliance and trust
Trust signalCompliance2 records
Langaware financial estimates
Financial estimateRevenue estimate
Valuation estimate
Langaware leadership team
Management profileNumber of profiles
Profiles15 records
Langaware subsidiaries and ownership
Company hierarchySubsidiaries1 record
Langaware funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Langaware M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Langaware
What does Langaware do?
LANGaware provides an AI-driven speech and language analysis platform that detects and monitors digital biomarkers of cognitive and mental health conditions. Customers record a brief speaking task; the platform applies proprietary multilingual biomarkers and machine learning classifiers to produce a clinical decision-support report (7 data points) for early detection of Mild Cognitive Impairment, Alzheimer's disease, and Depression. The platform is offered as enterprise SaaS to healthcare providers, payors, life sciences companies, corporate wellness programs, and digital health platforms, with an additional self-serve test option.
Is Langaware a public or private company?
Langaware is a private company. It is classified as venture growth investor backed and is currently operating.
When was Langaware founded?
Langaware was founded in 2017. It employs 11 to 50 people.
Where is Langaware based?
Langaware is headquartered in Menlo Park, United States, in the North America region.
How does Langaware make money?
One revenue line is on record: AI Health Screening Platform SaaS.
Who are Langaware's main competitors?
Direct peers on record are Cambridge Cognition, Altoida, Cogstate, Linus Health, BrainCheck, Ellipsis Health, Kintsugi and Neurotrack. Suki AI is listed as a broad incumbent. NeuraLight is listed as an emerging player.
Does Langaware have an API?
No public API is recorded for Langaware.
What industry is Langaware in?
Langaware's product category is Digital Health - Cognitive & Mental Health Screening Software. Its primary akta.pro industry code is HLACAAAI, Speech Recognition, Dictation & Medical Transcription Platforms, with a secondary code of HLACAOAB, eCOA/ePRO/eDiary & Patient-Facing Data Collection. Its NAICS code is 5182 and its SIC code is 7372.